N
NeuralStem
Neuralstem, a biotherapeutics company, aims to apply stem cell research and technology to treat diseases of the central nervous system
About NeuralStem
Seneca Biopharma, Inc. (NASDAQ: SNCA) is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases that currently lack effective medical solutions. Operating in the biopharmaceutical sector, Seneca focuses on identifying and acquiring promising new scientific assets and technologies. The company aims to build a robust pipeline of biopharmaceuticals, advancing these products through clinical development and ultimately commercializing them to create value for stakeholders.
Read full description
Seneca Biopharma serves a diverse range of clients, including patients with unmet medical needs, healthcare providers, and research institutions. The company operates primarily in the healthcare and biotechnology markets, targeting diseases where current treatment options are inadequate or non-existent.
Seneca's business model revolves around the acquisition and development of novel biopharmaceutical assets. By leveraging a network of trusted experts and advisors, the company evaluates new technologies and integrates them into its development pipeline. Revenue generation is anticipated through the successful commercialization of these biopharmaceutical products, either independently or through strategic partnerships.
At a glance
- Status
- Operational
- Founded
- 1996
- Headquarters
- Rockville, United States
- Listing
- IPO 2006
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 56.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Personal Health, Diabetes, Biotechnology, Neurology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning NeuralStem.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jul 2019 | $7.5M | — | Undisclosed | — |
| LATE VC✓Equity / VC | Dec 2016 | $20M | $80M | Tianjin Pharmaceutical Group | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | Profit | Margin |
|---|---|---|---|---|
| 2026 | $260K | 0% | −$15M | -5769.2% |
| 2025 | $260K | 0% | −$15M | -5769.2% |
| 2024 | $260K | 0% | −$15M | -5769.2% |
| 2023 | $260K | 0% | ||
| 2022 | $260K | 0% | ||
| 2021 | $260K | 0% | ||
| 2020 | $260K | — |
Growth signals
Latest recorded traffic for NeuralStem is 220 monthly website visits, up 4.8% over the last three months. NeuralStem's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
- TGTianjin Pharmaceutical Group
Other known investors2 additional known investors
Hercules Capital
Small Business Innovation Research
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about NeuralStem on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NeuralStem’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.